MMIT - Managed Markets Insight & Technology

23/01/2026

"[MMIT's new platform] lets us manipulate the initial landing page to see what we're most interested in as an organization. We can look at competitive coverage and restrictions side by side for any class, which is really nice. Then we can narrow it down as much as we want to a specific status or step."

- Director of National Accounts
Midsize Biopharmaceutical Company

Learn more about The MMIT Platform: https://vist.ly/4nw5m

MMIT’s Platform is a strategic leap forward—built to streamline how commercialization teams access insights, execute workflows, and make decisions.

22/01/2026

The new year starts with a moving target, and payer mix is already shifting. MMIT’s Q3 2025 Directory of Health Plans just dropped, giving you the clearest, most current view of where more than a million lives moved in a single quarter. https://vist.ly/4ntjf

22/01/2026

One Platform. One Experience. All of MMIT. ✔️

Introducing the MMIT Platform. This platform serves as a digital front door to access MMIT solutions, capabilities, and data.

Gain access to everything you need, all in one place. https://vist.ly/4nsbx

MMIT’s Platform is a strategic leap forward—built to streamline how commercialization teams access insights, execute workflows, and make decisions.

21/01/2026

https://vist.ly/4npv4 | In part two of our 2026 predictions, MMIT access experts discuss what’s coming next in oncology, the GLP-1/obesity market, and biosimilars, from expected launches to restructured approval pathways and AI-driven scalability.

21/01/2026

From early evidence to post-launch strategy, MMIT, powered by NorstellaLinQ, equips market access teams to anticipate access hurdles, validate payer behavior, and more with AI-enabled real-world insights. Meet us at to explore our end-to-end support across the product lifecycle.

Schedule a meeting with us at : https://vist.ly/4nmwp

20/01/2026

Better targeting starts with better visibility. https://vist.ly/4nhb7

This use case shows how MMIT, powered by NorstellaLinQ, helped a manufacturer identify nuanced patient cohorts hidden within structured and unstructured EMR data—transforming disease-state education and strengthening account-level strategy.

20/01/2026

REAL-WORLD DATA CONTENT HUB: Rare doesn’t mean unreachable. Our exclusive content hub demonstrates how NorstellaLinQ—pharma’s first fully integrated real-world data asset—combines structured and unstructured data to identify previously hidden patient populations, expedite diagnoses, and enhance targeting strategies.

Explore expert insights, real-world use cases, and strategies that close the gaps traditional data sources miss. Start here: https://vist.ly/4ngqb

19/01/2026

State bans are creating real pressure on copay adjustment programs, and payers are not responding the same way. Some revert to traditional benefit designs, others lobby to protect these programs, and about one‑third negotiate directly with manufacturers. MMIT’s Heather Roulston breaks down what these mixed responses mean for manufacturers and where there is room to influence future benefit design.

Read the full blog to understand what is changing and how to prepare:
https://vist.ly/4ncid

16/01/2026

https://vist.ly/4m2pe | In the second installment of our 2026 predictions blog, three MMIT market access experts share their thoughts on biosimilar market expansion, the impact of direct-to-consumer programs on PBMs, and what’s next for weight loss drugs.

15/01/2026

https://vist.ly/4mvrh | Determining whether a therapy is covered shouldn't be a matter of guesswork. In this infographic, see how both pharma and HIT companies can leverage BIN/PCN/Group data to pinpoint coverage with precision—down to the formulary and restriction level.

14/01/2026

Too often, development choices are made without understanding coverage and barriers to access. MMIT will be onsite at helping commercial and market access teams ensure the evidence generated during trials truly supports future coverage and adoption.

Schedule a meeting with us at : https://vist.ly/4mrpg

14/01/2026

What can pharma companies expect in 2026? https://vist.ly/4mr3b

In this Q&A, three MMIT access experts share what to look out for, from the role of AI in payer policy development to the growth of value-based contracting for high-volume medications.